First Turn Management LLC Lowers Stock Holdings in argenex SE $ARGX

First Turn Management LLC reduced its position in argenex SE (NASDAQ:ARGX) by 40.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 23,256 shares of the company’s stock after selling 15,511 shares during the period. argenex comprises approximately 2.2% of First Turn Management LLC’s holdings, making the stock its 23rd biggest holding. First Turn Management LLC’s holdings in argenex were worth $19,557,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. American Century Companies Inc. grew its stake in argenex by 11.6% in the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock worth $169,474,000 after acquiring an additional 23,864 shares during the period. US Bancorp DE grew its stake in argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after acquiring an additional 1,919 shares during the period. Sands Capital Management LLC purchased a new stake in argenex in the 3rd quarter worth approximately $12,262,000. Assenagon Asset Management S.A. purchased a new stake in argenex in the 4th quarter worth approximately $20,475,000. Finally, Fiera Capital Corp grew its stake in argenex by 12.1% in the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock worth $131,030,000 after acquiring an additional 19,180 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARGX has been the subject of several recent analyst reports. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Oppenheimer lowered their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Royal Bank Of Canada lowered their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Glj Research raised shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Stock Down 0.6%

Shares of NASDAQ ARGX opened at $893.52 on Friday. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The firm has a fifty day moving average of $812.09 and a 200-day moving average of $812.17. The stock has a market capitalization of $55.57 billion, a PE ratio of 39.78, a P/E/G ratio of 1.37 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.31 billion during the quarter. Equities research analysts expect that argenex SE will post 26.19 EPS for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.